Yeztugo showed 99.9% efficacy in preventing HIV in over 4,300 participants across two Phase 3 trials. FDA approved Yeztugo as the first twice-yearly injectable PrEP option for HIV prevention in the U.S. Get access to the leaderboards pointing to tomorrow's biggest stock movers.

- Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia ...

Aptose and Hanmi Pharmaceutical Enter New Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for ...

Social security. It's quite the topic. There are debates on whether it will survive over the long term. There are debates over how it should work. What's clear, though, is there are advantages and disadvantages in regards to when is the ideal time to take Social Security benefits.

TORONTO, June 20, 2025 ( GLOBE NEWSWIRE ) -- CHAR Technologies Ltd. ( "CHAR Tech" or the "Company" ) ( TSXV:YES ) a leader in sustainable energy solutions, announces that the Board of Directors has approved the amendment of up to 2,750,000 common share purchase warrants ( the "Warrants" ) .

- If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors ...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES ...

TORONTO, June 20, 2025 ( GLOBE NEWSWIRE ) -- CHAR Technologies Ltd. ( "CHAR Tech" or the "Company" ) YES a leader in sustainable energy solutions, announces that the Board of Directors has approved the amendment of up to 2,750,000 common share purchase warrants ( the "Warrants" ) .

MINNEAPOLIS, June 20, 2025 ( GLOBE NEWSWIRE ) -- PetVivo Holdings, Inc. ( OTCQB: PETV. OTCPINK: PETVW ) and its wholly-owned subsidiary PetVivo Animal Health, Inc. ( collectively "PetVivo" or the "Company" ) an emerging biomedical device company focused on the commercialization of innovative ...

Declares Dividend to be Paid August 15, 2025 Declares Dividend to be Paid August ...